Good morning everyone, and welcome to Wednesday, 8 November.

Aussie shares are poised to open flat on Wednesday after a mixed session on Wall Street. 

On Stockhead today…

After dumping a controversial mega iron ore project, can the former Flinders Mines reinvent itself as the king of the iron ore juniors? MD Steven Michael says the new development plan for rebadged Red Hawk Mining would see a small scale project of around 3Mtpa built for just $150 million.

A slowing global economy, along with recession concerns and geopolitical headwinds, have slowed capital raising in 2023. But ASX-listed Complii saw more than $10 billion raised through its platform in FY23. Eddy Sunarto reached out to Craig Mason, Executive Chairman of Complii.

And Guy le Page has called the “second boom” of uranium as just around the corner. Who’s he picking? This ASX junior.


But first..


Gold: US$1,983.80 (-0.43%)

Silver: US$23.14 (-0.27%)

Nickel (3mth): US$17,979/t (-0.19%)

Copper (3mth): US$8,143/t (+0.41%)

Oil (WTI): US$80.97 (+0.57%)

Oil (Brent): US$85.35 (+0.55%)

Iron 62pc Fe: US$126.15/t (+0.46%)

AUD/USD: 0.6509 (+0.03%)

Bitcoin: US$34,889 (-0.8%)



Barrick Gold’s Mark Bristow pours cold water on M&A, placing focus for C$40 billion gold giant on organic growth. Josh Chiat explored how the development of its Pakistan copper asset will help make the gold producer a major copper force, with 450,000t of output annually by 2031.

Prime Minister Anthony Albanese is in China to restore stability with Australia’s largest trading partner. So as Australia looks to improve trade with China, Nadine McGrath looks at which ASX stocks could stand to benefit.

And this…



Here are the best performing ASX small cap stocks:

Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin


Yesterday’s Small Caps highlights:

Aussie clinical stage immuno-oncology upstart, Imugene (ASX:IMU) dropped a promising clinical trial update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA).

Imugene CEO Leslie Chong says IMU’s Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development.

“The early positive response data we are seeing at the mid-dose level in hard-to-treat bile duct cancer suggests that VAXINIA may be a potent anti-cancer drug as we interrogate higher dose levels.

“With no adverse safety signals, thus allowing us to dose higher, VAXINIA will have a very high therapeutic window which is valuable in oncology drug development.”


Also higher on Tuesday was NickelSearch (ASX:NIS). The WA nickel sulphide explorer is having a +40% kind of week so far, and was up another 17% or so around Melbourne Cup time.



Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin



Reward Minerals (ASX:RWD) – Pending the release of an announcement in relation to a potential material acquisition

Impact Minerals (ASX:IPT) – Pending the release of the Lake Hope Scoping Study

Challenger Gold (ASX:CEL) – Pending the release to the market of a material announcement in relation to a Scoping Study for the Hualilan Gold Project in Argentina

Inca Minerals (ASX:ICG) – Pending an announcement regarding a capital raising